Cartesian Change In Cash from 2010 to 2026
| RNAC Stock | 6.76 0.45 6.24% |
Change In Cash | First Reported 2014-12-31 | Previous Quarter -20 M | Current Value -16.9 M | Quarterly Volatility 32.2 M |
Check Cartesian Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cartesian Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 0.0 or Selling General Administrative of 21.7 M, as well as many indicators such as Price To Sales Ratio of 13.03, Dividend Yield of 0.0 or Days Sales Outstanding of 8.94. Cartesian financial statements analysis is a perfect complement when working with Cartesian Therapeutics Valuation or Volatility modules.
Cartesian | Change In Cash | Build AI portfolio with Cartesian Stock |
Latest Cartesian Therapeutics' Change In Cash Growth Pattern
Below is the plot of the Change In Cash of Cartesian Therapeutics over the last few years. It is Cartesian Therapeutics' Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cartesian Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Change In Cash | 10 Years Trend |
|
Change In Cash |
| Timeline |
Cartesian Change In Cash Regression Statistics
| Arithmetic Mean | 32,945,870 | |
| Geometric Mean | 24,377,880 | |
| Coefficient Of Variation | 186.98 | |
| Mean Deviation | 46,252,051 | |
| Median | 8,535,000 | |
| Standard Deviation | 61,600,798 | |
| Sample Variance | 3794.7T | |
| Range | 197.5M | |
| R-Value | 0.55 | |
| Mean Square Error | 2810.3T | |
| R-Squared | 0.31 | |
| Significance | 0.02 | |
| Slope | 6,744,749 | |
| Total Sum of Squares | 60714.5T |
Cartesian Change In Cash History
About Cartesian Therapeutics Financial Statements
Cartesian Therapeutics stakeholders use historical fundamental indicators, such as Cartesian Therapeutics' Change In Cash, to determine how well the company is positioned to perform in the future. Although Cartesian Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cartesian Therapeutics' assets and liabilities are reflected in the revenues and expenses on Cartesian Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cartesian Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Change In Cash | 156.4 M | 164.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Check out the analysis of Cartesian Therapeutics Correlation against competitors. For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cartesian Therapeutics. If investors know Cartesian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cartesian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth 0.168 | Return On Assets |
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cartesian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cartesian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cartesian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.